Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Insmed's Other Operating Expense for the
three
months ended in Jun. 2026 was MXN36 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 was MXN137 Mil.
Insmed's quarterly Other Operating Expense
increased
from Dec. 2025 (MXN35 Mil) to Mar. 2026 (MXN38 Mil) but then
declined
from Mar. 2026 (MXN38 Mil) to Jun. 2026 (MXN36 Mil).
Insmed's annual Other Operating Expense
increased
from Dec. 2023 (MXN86 Mil) to Dec. 2024 (MXN105 Mil) and
increased
from Dec. 2024 (MXN105 Mil) to Dec. 2025 (MXN108 Mil).
The historical data trend for Insmed's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN137 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of MXN137 Mil mean?
Insmed (MEX:INSM) has a Other Operating Expense of MXN137 Mil as of Jun. 2026. Other operating expenses that a company records on its income statement. View historical data on Insmed and its competitors.
Is Insmed's Other Operating Expense too high?
Insmed's current Other Operating Expense is MXN137 Mil. Overall, Insmed has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Insmed's Other Operating Expense compare to INCY and BNTX?
Insmed's Other Operating Expense of MXN137 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Insmed and its competitors. Insmed's current Other Operating Expense is MXN137 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insmed stock overvalued right now?
Based on GuruFocus' analysis, Insmed (MEX:INSM) is currently considered Possible Value Trap. The stock's GF Value™ is MXN3,415.35, compared to a current price of MXN2,135.00 — trading 37.5% below its estimated fair value. The current Other Operating Expense is MXN137 Mil. Insmed's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Insmed (MEX:INSM), the current Other Operating Expense is MXN137 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insmed (MEX:INSM) Overvalued in 2026?
Based on GuruFocus' analysis, Insmed stock appears to be undervalued.
The current stock price of MXN2,135.00 is trading 37.5% below its estimated GF Value™ of MXN3,415.35.
GuruFocus considers Insmed to be Possible Value Trap.
Key valuation signals for MEX:INSM:
Other Operating Expense: MXN137 Mil
GF Value™: MXN3,415.35 vs. price of MXN2,135.00 (37.5% below fair value)
No single metric tells the full story. See the MEX:INSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
73GF Score
Get the complete analysis for MEX:INSM
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:INSM has been successfully added to your 
